Nasdaq: YARW/Biotechnology
Yarrow Bioscience Inc
New York, NY, United States
Company overview
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.